SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brommage R, DeLuca HF 1985 Evidence that 1,25-dihydroxyvitamin D3 is the physiologically active metabolite of vitamin D3. Endocr Rev 6:491511.
  • 2
    Reichel H, Koeffler HP, Norman AW 1989 The role of the vitamin D endocrine system in the health and disease. N Engl J Med 320:980991.
  • 3
    Hughes MR, Malloy PJ, Kieback DG, Kesterson RA, Pike WJ, Feldman D, O'Malley BW 1988 Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 242:17021705.
  • 4
    Marx SJ, Barsony J 1988 Tissue-selective that 1,25-dihydroxyvitamin D3 resistance: Novel applications of calciferols. J Bone Miner Res 3:481487.
  • 5
    Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T, Kato S 1997 Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16:391396.
  • 6
    Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay M 1997 Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94:98319835.
  • 7
    Lau K-HW, Baylink DJ 1999 Vitamin D therapy of osteoporosis: Plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295306.
  • 8
    Eastell R, Riggs BL 1997 Vitamin D and osteoporosis. In: FeldmanD, GlorieuxFH, PikeJW (eds.) Vitamin D. Academic Press, San Diego, CA, USA, pp. 695711.
  • 9
    Reid IR 1996 Vitamin D and its metabolites in the management of osteoporosis. In: MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis. Academic Press, San Diego, CA, USA, pp. 11691190.
  • 10
    Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345357.
  • 11
    Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Scully GES, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165176.
  • 12
    Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:35973602.
  • 13
    Raisz LG, Trummel CL, Holick MF, DeLuca HF 1972 1,25-Dihydroxycholecalciferol: A potent stimulator of bone resorption in tissue culture. Science 175:768769.
  • 14
    Shira-ishi A, Takeda S, Masaki T, Higucvhi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E 2000 Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: Distinct actions from estrogen. J Bone Miner Res 15:770779.
  • 15
    Shira-ishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E 1999 The advantage of alfacalcidol over native vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311316.
  • 16
    Ruegsegger P, Koller B, Muller R 1996 A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 58:2429.
  • 17
    Hildebrand T, Ruegsegger P 1997 A new method for the model independent assessment of thickness in three-dimensional images. J Microsc 185:6775.
  • 18
    Ikeda K, Ogata E 1999 The effect of vitamin D on osteoblasts ans osteoclasts. Curr Opin Orthop 10:339343.
  • 19
    Ikeda K, Ogata E 2000 Modulation of bone remodeling by active vitamin D: Its role in the treatment of osteoporosis. Mech Age Dev 116:103111.
  • 20
    Denis I, Cournot G, Lacroix H, Colin C, Zerath E, Pointillart A 2000 In vivo bone metabolism and ex vivo bone marrow osteoprogenitors in vitamin D-deprived pigs. Bone 26:491498.
  • 21
    Hayashi S-i, Miyamoto A, Yamane T, Kataoka H, Ogawa M, Sugawara S, Nishikawa S, Nishikawa S-I, Sudo T, Yamazaki H, Kunisada T 1997 Osteoclast precursors in bone marrow and peritoneal cavity. J Cell Physiol 170:241247.
  • 22
    Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T 1999 Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors. J Exp Med 190:17411754.
  • 23
    Shevde NK, Bendixen AC, Dienger KM, Pike WW 2000 Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression Proc Natl Acad Sci USA 97:78297834.
  • 24
    Liu M, Lee M-H, Cohen M, Bommakanti M, Freedman LP 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142153.
  • 25
    Cheng T, Rodrigues N, Dombkowski D, Stier S, Scadden DT 2000 Stem cell repopulation efficiency but not pool size is governed by p27Kip1. Nat Med 6:12351240.